Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Globally with over 10 million deaths per year, cancer is the most transversal disease across countries, cultures, and ethnicities, affecting both developed and developing regions. Tumorigenesis is dynamically altered by distinct events and can be lethal when untreated. Despite the innovative therapeutics available, multidrug resistance (MDR) to chemotherapy remains the major hindrance to the success of cancer therapy. The multiple mechanisms by which cancer cells evade cell death are diverse, indicating that MDR involves complex interconnected biological networks. Molecular profiling is currently able to stratify cancer into its distinct subtypes and help identify the best therapeutics, leading to "translational systems medicine". Highly specialized methodologies are generating a large amount of "omics" data - including epigenetics, genomics, transcriptomics, proteomics, metabolomics, as well as pharmacogenomics. Many of the resulting databases store data in non-standard formats, which need to be converted, interpreted, and merged into readable formats. The latest development of artificial intelligence (AI) methodologies and tools, coupled with advancements in large-scale data management and powerful graphic processing computing units, potentiate the integration of these large data sources into relevant biological networks, which will enhance our understanding of cancer MDR. In this review, we revisit common MDR mechanisms and compile a list of the most relevant "omics" public databases. We highlight examples of AI methods that are now decisively contributing to clear advances in cancer research, such as identification of new drugs from large databases and prediction of relevant drug, target, and system properties. An overview of several freely available "ready-to-use" algorithms is also provided. The described molecular scale AI algorithms and tools will undoubtedly guide important improvements in efficiency and efficacy of traditional methods of cancer diagnostics and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.002 · Cited by 6,086
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
A pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Three-dimensional folding and functional organization principles of the Drosophila genome
Sexton, T., Yaffe, E., Kenigsberg, E., Bantignies, F., Leblanc, B., Hoichman, M., Parrinello, H., Tanay, A., & Cavalli, G. (2012) · Cell · doi:10.1016/j.cell.2012.01.010 · Cited by 1,983
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
The Proteomics Identifications (PRIDE) database and associated tools: status in 2013
Vizcaíno, J. A., Côté, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster, J. M., Griss, J., Alpi, E., Birim, M., Contell, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1262 · Cited by 1,918
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
Shedding microvesicles: artefacts no more
Cocucci, E., Racchetti, G., & Meldolesi, J. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.11.003 · Cited by 1,742
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
PID: the Pathway Interaction Database
Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., & Buetow, K. H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn653 · Cited by 1,603
Comparative Analysis of Single-Cell RNA Sequencing Methods
Ziegenhain, C., Vieth, B., Parekh, S., Reinius, B., Guillaumet-Adkins, A., Smets, M., Leonhardt, H., Heyn, H., Hellmann, I., & Enard, W. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.023 · Cited by 1,494
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Cellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338
Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions
Picotti, P., & Aebersold, R. (2012) · Nature Methods · doi:10.1038/nmeth.2015 · Cited by 1,302
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
Architectural protein subclasses shape 3D organization of genomes during lineage commitment
Phillips-Cremins, J. E., Sauria, M. E. G., Sanyal, A., Gerasimova, T. I., Lajoie, B. R., Bell, J. S. K., Ong, C.-T., Hookway, T. A., Guo, C., Sun, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.053 · Cited by 1,187
Computational and analytical challenges in single-cell transcriptomics
Stegle, O., Teichmann, S. A., & Marioni, J. C. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3833 · Cited by 1,170
Senescence-associated reprogramming promotes cancer stemness
Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., Dörr, J. R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I. A., et al. (2018) · Nature · doi:10.1038/nature25167 · Cited by 1,131
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Interpretation of Shotgun Proteomic Data
Nesvizhskii, A. I., & Aebersold, R. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r500012-mcp200 · Cited by 1,025
Identification of bioactive metabolites using activity metabolomics
Rinschen, M. M., Ivanisevic, J., Giera, M., & Siuzdak, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0108-4 · Cited by 1,008
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Deep learning in cancer diagnosis, prognosis and treatment selection
Tran, K. A., Kondrashova, O., Bradley, A., Williams, E. D., Pearson, J. V., & Waddell, N. (2021) · Genome Medicine · doi:10.1186/s13073-021-00968-x · Cited by 932
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Hutter, C., & Zenklusen, J. C. (2018) · Cell · doi:10.1016/j.cell.2018.03.042 · Cited by 871
Tumor-associated macrophages: from basic research to clinical application
Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803
Integrating high-throughput and computational data elucidates bacterial networks
Covert, M. W., Knight, E. M., Reed, J. L., Herrgard, M. J., & Palsson, B. O. (2004) · Nature · doi:10.1038/nature02456 · Cited by 792
Scaling single-cell genomics from phenomenology to mechanism
Tanay, A., & Regev, A. (2017) · Nature · doi:10.1038/nature21350 · Cited by 792
Gene regulatory network inference: Data integration in dynamic models—A review
Hecker, M., Lambeck, S., Toepfer, S., van Someren, E., & Guthke, R. (2009) · Biosystems · doi:10.1016/j.biosystems.2008.12.004 · Cited by 755
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target
Horvath, S., Zhang, B., Carlson, M., Lu, K. V., Zhu, S., Felciano, R. M., Laurance, M. F., Zhao, W., Qi, S., Chen, Z., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608396103 · Cited by 641
Tabb, D. L., Vega-Montoto, L., Rudnick, P. A., Variyath, A. M., Ham, A.-J. L., Bunk, D. M., Kilpatrick, L. E., Billheimer, D. D., Blackman, R. K., Cardasis, H. L., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr9006365 · Cited by 551
Rivera, C. M., & Ren, B. (2013) · Cell · doi:10.1016/j.cell.2013.09.011 · Cited by 550
Computed structures of core eukaryotic protein complexes
Humphreys, I. R., Pei, J., Baek, M., Krishnakumar, A., Anishchenko, I., Ovchinnikov, S., Zhang, J., Ness, T. J., Banjade, S., Bagde, S. R., et al. (2021) · Science · doi:10.1126/science.abm4805 · Cited by 542
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Bonneau, R., Reiss, D. J., Shannon, P., Facciotti, M., Hood, L., Baliga, N. S., & Thorsson, V. (2006) · Genome Biology · doi:10.1186/gb-2006-7-5-r36 · Cited by 510
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Pattern discovery and cancer gene identification in integrated cancer genomic data
Mo, Q., Wang, S., Seshan, V. E., Olshen, A. B., Schultz, N., Sander, C., Powers, R. S., Ladanyi, M., & Shen, R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208949110 · Cited by 474
TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471
Liu, X., & Locasale, J. W. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.01.004 · Cited by 453
Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R
Wilhelm, K., Ganesan, J., Müller, T., Dürr, C., Grimm, M., Beilhack, A., Krempl, C. D., Sorichter, S., Gerlach, U. V., Jüttner, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2242 · Cited by 435
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
DGIdb 2.0: mining clinically relevant drug–gene interactions
Wagner, A. H., Coffman, A. C., Ainscough, B. J., Spies, N. C., Skidmore, Z. L., Campbell, K. M., Krysiak, K., Pan, D., McMichael, J. F., Eldred, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1165 · Cited by 413
An unbiased oncology compound screen to identify novel combination strategies
O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Inoue, F., Kircher, M., Martin, B., Cooper, G. M., Witten, D. M., McManus, M. T., Ahituv, N., & Shendure, J. (2017) · Genome Research · doi:10.1101/gr.212092.116 · Cited by 331
ALIX and the multivesicular endosome: ALIX in Wonderland
Bissig, C., & Gruenberg, J. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.10.009 · Cited by 323
NEMO: cancer subtyping by integration of partial multi-omic data
Rappoport, N., & Shamir, R. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz058 · Cited by 286
The enterocyte microvillus is a vesicle-generating organelle
McConnell, R. E., Higginbotham, J. N., Shifrin, D. A., Tabb, D. L., Coffey, R. J., & Tyska, M. J. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200902147 · Cited by 260
Enhancer and promoter interactions—long distance calls
Krivega, I., & Dean, A. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.11.001 · Cited by 225
Yang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215
CancerMine: a literature-mined resource for drivers, oncogenes and tumor suppressors in cancer
Lever, J., Zhao, E. Y., Grewal, J., Jones, M. R., & Jones, S. J. M. (2019) · Nature Methods · doi:10.1038/s41592-019-0422-y · Cited by 205
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Kazachenka, A., Bertozzi, T. M., Sjoberg-Herrera, M. K., Walker, N., Gardner, J., Gunning, R., Pahita, E., Adams, S., Adams, D., & Ferguson-Smith, A. C. (2018) · Cell · doi:10.1016/j.cell.2018.09.043 · Cited by 181
Jiang, Y., Jin, C., Yu, H., Wu, J., Chen, C., Yuan, Q., Huang, W., Hu, Y., Xu, Y., Zhou, Z., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000003778 · Cited by 169
Qian, Y., Wang, X., Liu, Y., Li, Y., Colvin, R. A., Tong, L., Wu, S., & Chen, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.008 · Cited by 149
Beck, J. T., Rammage, M., Jackson, G. P., Preininger, A. M., Dankwa-Mullan, I., Roebuck, M. C., Torres, A., Holtzen, H., Coverdill, S. E., Williamson, M. P., et al. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00079 · Cited by 127
TGF-β: An emerging player in drug resistance
Brunen, D., Willems, S., Kellner, U., Midgley, R., Simon, I., & Bernards, R. (2013) · Cell Cycle · doi:10.4161/cc.26034 · Cited by 124
Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, M., Papaccio, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3319 · Cited by 122
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
The evolution of genome-scale models of cancer metabolism
Lewis, N. E., & Abdel-Haleem, A. M. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00237 · Cited by 87
Crossed wires: 3D genome misfolding in human disease
Norton, H. K., & Phillips-Cremins, J. E. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201611001 · Cited by 57
Naulaerts, S., Dang, C. C., & Ballester, P. J. (2017) · Oncotarget · doi:10.18632/oncotarget.20923 · Cited by 41
Research works printed but not linked: 518
- Akao, 2014, Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells, Int. J. Mol. Sci., 15, 1392, 10.3390/ijms15011392 · DOI
- Akesson, 2004, Integration of gene expression data into genome-scale metabolic models, Metab. Eng., 6, 285, 10.1016/j.ymben.2003.12.002 · DOI · Paper page
- Akhand, 2015, Context likelihood of relatedness with maximal information coefficient for Gene regulatory network inference, 2015 18th International Conference on Computer and Information Technology (ICCIT), 312
- Alaoui-Jamali, 2004, Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling, Drug Resist. Updat., 7, 245, 10.1016/j.drup.2004.06.004 · DOI
- Aldrich, 1979, Pleiotropic phenotype of cultured murine cells resistant to Maytansine, vincristine, colchicine, and Adriamycin23, J. Natl. Cancer Inst., 63, 751, 10.1093/jnci/63.3.751 · doi:10.1093/jnci/63.3.751
- Alexov, 2011, Progress in the prediction of pKa values in proteins, Proteins, 79, 3260, 10.1002/prot.23189 · DOI · Paper page
- Alfarouk, 2011, Tumor acidity as evolutionary spite, Cancers, 3, 408, 10.3390/cancers3010408 · DOI
- Alfarouk, 2015, Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp, Cancer Cell Int., 15, 71, 10.1186/s12935-015-0221-1 · DOI · Paper page
- Allison, 1974, Lysosomes in cancer cells, J. Clin. Pathol. Suppl., 7, 43, 10.1136/jcp.s3-7.1.43 · doi:10.1136/jcp.s3-7.1.43
- Al-Nedawi, 2008, Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells, Nat. Cell Biol., 10, 619, 10.1038/ncb1725 · DOI · Paper page
- Alonso-López, 2016, APID interactomes: providing proteome-based interactomes with controlled quality for multiple species and derived networks, Nucleic Acids Res., 44, W529, 10.1093/nar/gkw363 · DOI · Paper page
- Altelaar, 2012, Trends in ultrasensitive proteomics, Curr. Opin. Chem. Biol., 16, 206, 10.1016/j.cbpa.2011.12.011 · DOI
- Alvares, 2021, Modulatory effects of acidic pH and membrane potential on the adsorption of pH-Sensitive peptides to anionic lipid membrane, Membranes, 11
- An, 2017, Regulation of multidrug resistance by microRNAs in anti-cancer therapy, Acta Pharm. Sin. B, 7, 38, 10.1016/j.apsb.2016.09.002 · DOI · Paper page
- Anandakrishnan, 2012, H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations, Nucleic Acids Res., 40, W537, 10.1093/nar/gks375 · DOI · Paper page
- Andrei, 2020, Advanced technological tools to study multidrug resistance in cancer, Drug Resist. Updat., 48, 10.1016/j.drup.2019.100658 · DOI
- Anemone, 2019, Imaging tumor acidosis: a survey of the available techniques for mapping in vivo tumor pH, Cancer Metastasis Rev., 38, 25, 10.1007/s10555-019-09782-9 · DOI · Paper page
- Antonioli, 2013, CD39 and CD73 in immunity and inflammation, Trends Mol. Med., 19, 355, 10.1016/j.molmed.2013.03.005 · DOI · Paper page
- Antosiewicz, 2020, Constant-pH brownian dynamics simulations of a protein near a charged surface, ACS Omega, 5, 30282, 10.1021/acsomega.0c04817 · DOI
- Anusuya, 2018, Drug-target interactions: prediction methods and applications, Curr. Protein Pept. Sci., 19, 537, 10.2174/1389203718666161108091609 · DOI
- Assaraf, 2019, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist. Updat., 46, 10.1016/j.drup.2019.100645 · DOI · Paper page
- Balbin, 2013, Abstract 5214: reconstructing targetable pathways in KRAS dependent lung cancer by integrating transcriptome, proteome and phosphoproteome, Mol. Cell. Biol.
- Baldo, 2013, Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch, Cancer Metastasis Rev., 32, 723, 10.1007/s10555-013-9447-3 · DOI
- Baptista, 2002, Constant-pH molecular dynamics using stochastic titration, J. Chem. Phys., 117, 4184, 10.1063/1.1497164 · DOI · Paper page
- Barbarino, 2018, PharmGKB: a worldwide resource for pharmacogenomic information, Wiley Interdiscip. Rev. Syst. Biol. Med., 10, e1417, 10.1002/wsbm.1417 · DOI · Paper page
- Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
- Barrett, 2013, NCBI GEO: archive for functional genomics data sets--update, Nucleic Acids Res., 41, D991, 10.1093/nar/gks1193 · DOI · Paper page
- Bar-Zeev, 2017, Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance, Drug Resist. Updat., 31, 15, 10.1016/j.drup.2017.05.002 · DOI · Paper page
- Bashashati, 2013, Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling, J. Pathol., 231, 21, 10.1002/path.4230 · DOI · Paper page
- Baskin, 1981, Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells, Proc. Natl. Acad. Sci. U. S. A., 78, 3654, 10.1073/pnas.78.6.3654 · doi:10.1073/pnas.78.6.3654
- Bebawy, 2009, Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells, Leukemia, 23, 1643, 10.1038/leu.2009.76 · DOI · Paper page
- Berglund, 2021, Accessible pipeline for translational research using TCGA: examples of relating gene mechanism to disease-specific outcomes, Methods Mol. Biol., 2194, 127, 10.1007/978-1-0716-0849-4_8 · DOI
- Bhattacharya, 2014, GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways, PLoS One, 9, 10.1371/journal.pone.0114409 · DOI
- Bhola, 2013, TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer, J. Clin. Invest., 123, 1348, 10.1172/JCI65416 · DOI · Paper page
- Binenbaum, 2015, Gemcitabine resistance in pancreatic ductal adenocarcinoma, Drug Resist. Updat., 23, 55, 10.1016/j.drup.2015.10.002 · DOI · Paper page
- Blagosklonny, 2004, Analysis of FDA approved anticancer drugs reveals the future of cancer therapy, Cell Cycle, 3, 1035, 10.4161/cc.3.8.1023 · DOI
- Bleakley, 2009, Supervised prediction of drug-target interactions using bipartite local models, Bioinformatics, 25, 2397, 10.1093/bioinformatics/btp433 · DOI · Paper page
- Bonacich, 1987, Power and centrality: a family of measures, Am. J. Sociol., 92, 1170, 10.1086/228631 · DOI · Paper page
- Booth, 1961, An enzyme from rat liver catalysing conjugations with glutathione, Biochem. J., 79, 516, 10.1042/bj0790516 · DOI · Paper page
- Borst, 2012, Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?, Open Biol., 2, 10.1098/rsob.120066 · DOI · Paper page
- Bouvy, 2017, Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo, Leuk. Res., 62, 70, 10.1016/j.leukres.2017.09.014 · DOI
- Brabbs, 1979, Isolation and characterization of bleomycin-resistant clones of CHO cells, Genet. Res., 34, 269, 10.1017/S0016672300019509 · doi:10.1017/s0016672300019509
- Bradley, 1988, Mechanism of multidrug resistance, Biochim. Biophys. Acta, 948, 87
- Bulusu, 2014, canSAR: updated cancer research and drug discovery knowledgebase, Nucleic Acids Res., 42, D1040, 10.1093/nar/gkt1182 · DOI · Paper page
- Burnstock, 2013, Purinergic signalling and cancer, Purinergic Signal., 9, 491, 10.1007/s11302-013-9372-5 · DOI · Paper page
- Burrell, 2014, Tumour heterogeneity and the evolution of polyclonal drug resistance, Mol. Oncol., 8, 1095, 10.1016/j.molonc.2014.06.005 · DOI · Paper page
- Cai, 2021, Protein pKa prediction with machine learning, ChemRxiv
- Cancer Genome Atlas Research Network, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 · DOI · Paper page
- Cancer Genome Atlas Research Network, 2013, The Cancer genome atlas pan-cancer analysis project, Nat. Genet., 45, 1113, 10.1038/ng.2764 · DOI · Paper page
- Cao, 2020, Towards the overcoming of anticancer drug resistance mediated by p53 mutations, Drug Resist. Updat., 49, 10.1016/j.drup.2019.100671 · DOI · Paper page
- Care, 2019, Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer, NPJ Syst. Biol. Appl., 5, 13, 10.1038/s41540-019-0090-7 · DOI
- Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov., 2, 401, 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
- Challagundla, 2015, Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy, J. Natl. Cancer Inst., 107
- Charitou, 2016, Using biological networks to integrate, visualize and analyze genomics data, Genet. Sel. Evol., 48, 27, 10.1186/s12711-016-0205-1 · DOI
- Chatterjee, 2018, The multifaceted role of glutathione S-transferases in cancer, Cancer Lett., 433, 33, 10.1016/j.canlet.2018.06.028 · DOI · Paper page
- Checa-Rojas, 2018, GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer, Oncotarget, 9, 21696, 10.18632/oncotarget.24796 · DOI
- Chen, 2007, Key aspects of analyzing microarray gene-expression data, Pharmacogenomics, 8, 473, 10.2217/14622416.8.5.473 · DOI
- Chen, 2002, TTD: therapeutic target database, Nucleic Acids Res., 30, 412, 10.1093/nar/30.1.412 · DOI · Paper page
- Chen, 2014, Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs, Tumour Biol., 35, 9649, 10.1007/s13277-014-2242-0 · DOI
- Chen, 2014, Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs, PLoS One, 9
- Chen, 2015, The Warburg effect: evolving interpretations of an established concept, Free Radic. Biol. Med., 79, 253, 10.1016/j.freeradbiomed.2014.08.027 · DOI · Paper page
- Chen, 2017, Long non-coding RNAs in anti-cancer drug resistance, Oncotarget, 8, 1925, 10.18632/oncotarget.12461 · DOI · Paper page
- Chen, 2018, Predict effective drug combination by deep belief network and ontology fingerprints, J. Biomed. Inform., 85, 149, 10.1016/j.jbi.2018.07.024 · DOI · Paper page
- Chen, 2021, Establishing a consensus for the hallmarks of cancer based on gene ontology and pathway annotations, BMC Bioinformatics, 22, 178, 10.1186/s12859-021-04105-8 · DOI
- Cheng, 2019, Network-based prediction of drug combinations, Nat. Commun., 10, 1197, 10.1038/s41467-019-09186-x · DOI · Paper page
- Chitnis, 1978, Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukemia to emetine, an inhibitor of protein synthesis, J. Natl. Cancer Inst., 60, 1049, 10.1093/jnci/60.5.1049 · doi:10.1093/jnci/60.5.1049
- Chiu, 2018, scdNet: a computational tool for single-cell differential network analysis, BMC Syst. Biol., 12, 124, 10.1186/s12918-018-0652-0 · DOI
- Chiu, 2019, Correction to: predicting drug response of tumors from integrated genomic profiles by deep neural networks, BMC Med. Genomics
- Choi, 2014, ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development, Curr. Pharm. Des., 20, 793, 10.2174/138161282005140214165212 · DOI · Paper page
- Cieślik, 2018, Cancer transcriptome profiling at the juncture of clinical translation, Nat. Rev. Genet., 19, 93, 10.1038/nrg.2017.96 · DOI · Paper page
- Cohen, 2021, Targeted nanomedicine modalities for prostate cancer treatment, Drug Resist. Updat., 56, 10.1016/j.drup.2021.100762 · DOI
- Collier, 1970, Spotted necrosis of the tarsal conjunctiva in a case of progressive scleroderma, Bull. Soc. Ophtalmol. Fr., 70, 818
- Colombo, 2013, Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles, J. Cell. Sci., 126, 5553
- Conesa, 2019, Making multi-omics data accessible to researchers, Sci. Data, 6, 251, 10.1038/s41597-019-0258-4 · DOI · Paper page
- Connor, 2010, The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib, Thromb. Haemost., 103, 1044, 10.1160/TH09-09-0644 · DOI · Paper page
- Consolino, 2020, Non-invasive investigation of tumor metabolism and acidosis by MRI-CEST imaging, Front. Oncol., 10, 161, 10.3389/fonc.2020.00161 · DOI
- Corcoran, 2014, miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression, Prostate, 74, 1320, 10.1002/pros.22848 · DOI · Paper page
- Costa, 2008, Complex networks: the key to systems biology, Genet. Mol. Biol., 31, 591, 10.1590/S1415-47572008000400001 · DOI
- Crecelius, 2015, MALDI mass spectrometric imaging meets “omics”: recent advances in the fruitful marriage, Analyst, 140, 5806, 10.1039/C5AN00990A · DOI
- Cuellar, 2018, BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, J. Oncol. Pharm. Pract., 24, 433, 10.1177/1078155217710553 · DOI
- Cui, 2010, A network of cancer genes with co-occurring and anti-co-occurring mutations, PLoS One, 5
- Czowski, 2020, Cancer and pH dynamics: transcriptional regulation, proteostasis, and the need for new molecular tools, Cancers, 12
- Daniel, 2013, The role of proton dynamics in the development and maintenance of multidrug resistance in cancer, Biochim. Biophys. Acta, 1832, 606, 10.1016/j.bbadis.2013.01.020 · DOI
- Danø, 1995, The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion, Nihon Kessen Shiketsu Gakkai shi, 6, 212, 10.2491/jjsth.6.212 · DOI · Paper page
- Das, 2020, Integration of online omics-data resources for Cancer research, Front. Genet., 11, 10.3389/fgene.2020.578345 · DOI
- de Angelis, 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil, Int. J. Oncol., 24, 1279
- De Angelis, 2006, Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery, Mol. Cancer, 5, 20, 10.1186/1476-4598-5-20 · DOI · Paper page
- De Las Rivas, 2018, Human interactomics: comparative analysis of different protein interaction resources and construction of a Cancer protein-Drug bipartite network, Adv. Protein Chem. Struct. Biol., 111, 263, 10.1016/bs.apcsb.2017.09.002 · DOI
- Dean, 2005, Tumour stem cells and drug resistance, Nat. Rev. Cancer, 5, 275, 10.1038/nrc1590 · DOI · Paper page
- Debenham, 1982, DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression, Mol. Cell. Biol., 2, 881
- Deeley, 2006, Substrate recognition and transport by multidrug resistance protein 1 (ABCC1), FEBS Lett., 580, 1103, 10.1016/j.febslet.2005.12.036 · DOI · Paper page
- Dekker, 2002, Capturing chromosome conformation, Science, 295, 1306, 10.1126/science.1067799 · DOI · Paper page
- Del Conde, 2005, Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation, Blood, 106, 1604, 10.1182/blood-2004-03-1095 · DOI · Paper page
- Deli, 2007, Functional genomics of calcium channels in human melanoma cells, Int. J. Cancer, 121, 55, 10.1002/ijc.22621 · DOI
- Demel, 2009, Predicting ligand interactions with ABC transporters in ADME, Chem. Biodivers., 6, 1960, 10.1002/cbdv.200900138 · DOI
- Deng, 2016, Twist mediates an aggressive phenotype in human colorectal cancer cells, Int. J. Oncol., 48, 1117, 10.3892/ijo.2016.3342 · DOI · Paper page
- Desiere, 2005, Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry, Genome Biol., 6, R9, 10.1186/gb-2004-6-1-r9 · DOI · Paper page
- Di Virgilio, 2009, P2X(7): a growth-promoting receptor-implications for cancer, Purinergic Signal., 5, 251, 10.1007/s11302-009-9145-3 · DOI
- Díez-Villanueva, 2015, Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer, Epigenetics Chromatin, 8, 22, 10.1186/s13072-015-0014-8 · DOI · Paper page
- Dixon, 2012, Topological domains in mammalian genomes identified by analysis of chromatin interactions, Nature, 485, 376, 10.1038/nature11082 · DOI · Paper page
- Dorman, 2016, Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning, Mol. Oncol., 10, 85, 10.1016/j.molonc.2015.07.006 · DOI · Paper page
- Du, 2016, Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in Cancer, Molecules, 21
- Edelman, 2017, Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy, Oncotarget, 8, 24337, 10.18632/oncotarget.15363 · DOI
- Edgar, 2002, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, Nucleic Acids Res., 30, 207, 10.1093/nar/30.1.207 · DOI · Paper page
- Edwards, 2015, The CPTAC data portal: a resource for Cancer proteomics research, J. Proteome Res., 14, 2707, 10.1021/pr501254j · DOI · Paper page
- Ender, 2019, Extracellular vesicles: subcellular organelles with the potential to spread Cancer resistance, Anticancer Res., 39, 3395, 10.21873/anticanres.13483 · DOI
- Engelberg, 2019, Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo, Cell Death Dis., 10, 702, 10.1038/s41419-019-1870-0 · DOI
- Engelberg, 2021, Targeted nanoparticles harboring Jasmine-oil-entrapped paclitaxel for elimination of lung cancer cells, Int. J. Mol. Sci., 22, 1019, 10.3390/ijms22031019 · DOI
- Eramo, 2006, Chemotherapy resistance of glioblastoma stem cells, Cell Death Differ., 13, 1238, 10.1038/sj.cdd.4401872 · DOI · Paper page
- Erić, 2014, Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein, SAR QSAR Environ. Res., 25, 939, 10.1080/1062936X.2014.976265 · DOI
- Fais, 2010, Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism, J. Intern. Med., 267, 515, 10.1111/j.1365-2796.2010.02225.x · DOI
- Falkner, 2007, ProteomeCommons.oRg IO Framework: reading and writing multiple proteomics data formats, Bioinformatics, 23, 262, 10.1093/bioinformatics/btl573 · DOI
- Falzoni, 2013, Detecting adenosine triphosphate in the pericellular space, Interface Focus, 3, 10.1098/rsfs.2012.0101 · DOI · Paper page
- Fan, 2020, Single-cell transcriptomics in cancer: computational challenges and opportunities, Exp. Mol. Med., 52, 1452, 10.1038/s12276-020-0422-0 · DOI · Paper page
- Federici, 2014, Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin, PLoS One, 9, 10.1371/journal.pone.0088193 · DOI · Paper page
- Ferlay, 2021, Cancer statistics for the year 2020: an overview, Int. J. Cancer, 149, 778, 10.1002/ijc.33588 · DOI · Paper page
- Filippini, 1990, Extracellular ATP in T-lymphocyte activation: possible role in effector functions, Proc. Natl. Acad. Sci. U. S. A., 87, 8267, 10.1073/pnas.87.21.8267 · DOI · Paper page
- Fiore, 2017, Collaboration to accelerate proteogenomics Cancer care: the department of veterans affairs, department of defense, and the national Cancer institute’s applied proteogenomics OrganizationaL learning and outcomes (APOLLO) network, Clin. Pharmacol. Ther., 101, 619, 10.1002/cpt.658 · DOI
- Fogolari, 2012, Bluues: a program for the analysis of the electrostatic properties of proteins based on generalized Born radii, BMC Bioinformatics, 13, S18, 10.1186/1471-2105-13-S4-S18 · DOI
- Forbes, 2010, COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer, Nucleic Acids Res., 38, D652, 10.1093/nar/gkp995 · DOI · Paper page
- Fotoohi, 2004, Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy, Blood, 104, 4194, 10.1182/blood-2004-04-1493 · doi:10.1182/blood-2004-04-1493
- Fouladiha, 2017, Biomedical applications of cell- and tissue-specific metabolic network models, J. Biomed. Inform., 68, 35, 10.1016/j.jbi.2017.02.014 · DOI
- Frank, 2010, The therapeutic promise of the cancer stem cell concept, J. Clin. Invest., 120, 41, 10.1172/JCI41004 · DOI · Paper page
- Freeman, 1977, A set of measures of centrality based on betweenness, Sociometry, 40, 35, 10.2307/3033543 · DOI · Paper page
- Frei, 1961, Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and Methotrexate, Blood, 18, 431, 10.1182/blood.V18.4.431.431 · DOI · Paper page
- Fruehauf, 2006, In vitro drug response and molecular markers associated with drug resistance in malignant gliomas, Clin. Cancer Res., 12, 4523, 10.1158/1078-0432.CCR-05-1830 · DOI
- Gacche, 2018, Redundant angiogenic signaling and tumor drug resistance, Drug Resist. Updat., 36, 47, 10.1016/j.drup.2018.01.002 · DOI
- Galluzzi, 2012, Enlightening the impact of immunogenic cell death in photodynamic cancer therapy, EMBO J., 10.1038/emboj.2012.2 · DOI
- Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107 · DOI · Paper page
- Ganapathy-Kanniappan, 2013, Tumor glycolysis as a target for cancer therapy: progress and prospects, Mol. Cancer, 12, 152, 10.1186/1476-4598-12-152 · DOI · Paper page
- Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, l1, 10.1126/scisignal.2004088 · DOI · Paper page
- Gao, 2019, Before and after: comparison of legacy and harmonized TCGA genomic data commons’ data, Cell Syst., 9
- Gao, 2021, Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function, Drug Resist. Updat., 57, 10.1016/j.drup.2021.100770 · DOI
- Garofalo, 2013, MicroRNAs as therapeutic targets in chemoresistance, Drug Resist. Updat., 16, 47, 10.1016/j.drup.2013.05.001 · DOI · Paper page
- Geng, 2013, The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer, Diagn. Pathol., 8, 198, 10.1186/1746-1596-8-198 · DOI
- Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N. Engl. J. Med., 366, 883, 10.1056/NEJMoa1113205 · DOI · Paper page
- Gillet, 2010, Mechanisms of multidrug resistance in cancer, Methods Mol. Biol., 596, 47, 10.1007/978-1-60761-416-6_4 · DOI · Paper page
- Gillet, 2012, Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma, Clin. Cancer Res., 18, 3197, 10.1158/1078-0432.CCR-12-0056 · DOI
- Gilson, 2016, BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology, Nucleic Acids Res., 44, D1045, 10.1093/nar/gkv1072 · DOI · Paper page
- Glaves, 2011, Generation and analysis of transcriptomics data, Methods Mol. Biol., 691, 167, 10.1007/978-1-60761-849-2_10 · doi:10.1007/978-1-60761-849-2_10
- Gokcan, 2021, Prediction of protein pKa with representation learning, ChemRxiv.
- Goldenberg, 2019, A new era: artificial intelligence and machine learning in prostate cancer, Nat. Rev. Urol., 16, 391, 10.1038/s41585-019-0193-3 · DOI · Paper page
- Goldman, 2019, The UCSC Xena platform for public and private cancer genomics data visualization and interpretation, bioRxiv.
- Goler-Baron, 2011, Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance, PLoS One, 6, 10.1371/journal.pone.0016007 · DOI
- Goler-Baron, 2012, Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells, Biochem. Pharmacol., 83, 1340, 10.1016/j.bcp.2012.01.033 · DOI
- Golub, 1999, Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, Science, 286, 531, 10.1126/science.286.5439.531 · DOI · Paper page
- Gomes de Oliveira Dal’Molin, 2015, A multi-tissue genome-scale metabolic modeling framework for the analysis of whole plant systems, Front. Plant Sci., 6, 4
- Gonen, 2012, Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance, Drug Resist. Updat., 15, 183, 10.1016/j.drup.2012.07.002 · DOI · Paper page
- Gong, 2013, DeconRNASeq: a statistical framework for deconvolution of heterogeneous tissue samples based on mRNA-Seq data, Bioinformatics, 29, 1083, 10.1093/bioinformatics/btt090 · DOI · Paper page
- Gordon, 2012, Cellular senescence and cancer chemotherapy resistance, Drug Resist. Updat., 15, 123, 10.1016/j.drup.2012.01.002 · DOI · Paper page
- Gottesman, 2002, Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615, 10.1146/annurev.med.53.082901.103929 · DOI · Paper page
- Gottesman, 2016, Toward a better understanding of the complexity of Cancer drug resistance, Annu. Rev. Pharmacol. Toxicol., 56, 85, 10.1146/annurev-pharmtox-010715-103111 · DOI · Paper page
- Govindarajan, 2012, Microarray and its applications, J. Pharm. Bioallied Sci., 4, S310, 10.4103/0975-7406.100283 · doi:10.4103/0975-7406.100283
- Gracie, 2011, An integrated systems biology approach to the study of preterm birth using “-omic” technology--a guideline for research, BMC Pregnancy Childbirth, 11, 71, 10.1186/1471-2393-11-71 · DOI
- Graumann, 2012, A framework for intelligent data acquisition and real-time database searching for shotgun proteomics, Mol. Cell Proteomics, 11, 10.1074/mcp.M111.013185 · DOI · Paper page
- Greenfield, 2013, Robust data-driven incorporation of prior knowledge into the inference of dynamic regulatory networks, Bioinformatics, 29, 1060, 10.1093/bioinformatics/btt099 · DOI · Paper page
- Grillo-Hill, 2015, Increased H+ efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression, Elife, 4
- Griss, 2020, ReactomeGSA - efficient multi-omics comparative pathway analysis, Mol. Cell Proteomics, 19, 2115, 10.1074/mcp.TIR120.002155 · DOI · Paper page
- Grünewald, 2020, Titratable Martini model for constant pH simulations, J. Chem. Phys., 153, 10.1063/5.0014258 · DOI · Paper page
- GTEx Consortium, Laboratory, 2017, Genetic effects on gene expression across human tissues, Nature, 550, 204, 10.1038/nature24277 · DOI · Paper page
- Gulhan, 2019, Detecting the mutational signature of homologous recombination deficiency in clinical samples, Nat. Genet., 51, 912, 10.1038/s41588-019-0390-2 · DOI · Paper page
- Günakan, 2019, A novel prediction method for lymph node involvement in endometrial cancer: machine learning, Int. J. Gynecol. Cancer, 29, 320, 10.1136/ijgc-2018-000033 · DOI
- Guo, 2014, Network-based identification of biomarkers coexpressed with multiple pathways, Cancer Inform., 13, 37
- Guo, 2016, SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets, Nucleic Acids Res., 44, D1011, 10.1093/nar/gkv1108 · DOI
- Gupta, 2020, tpHusion: an efficient tool for clonal pH determination in Drosophila, PLoS One, 15, 10.1371/journal.pone.0228995 · DOI
- Ha, 2019, Prior to initiation of chemotherapy, can we predict breast tumor response? Deep learning convolutional neural networks approach using a breast MRI tumor dataset, J. Digit. Imaging, 32, 693, 10.1007/s10278-018-0144-1 · DOI
- Haenisch, 2014, MicroRNAs and their relevance to ABC transporters, Br. J. Clin. Pharmacol., 77, 587, 10.1111/bcp.12251 · DOI
- Halling-Brown, 2012, canSAR: an integrated cancer public translational research and drug discovery resource, Nucleic Acids Res., 40, D947, 10.1093/nar/gkr881 · DOI · Paper page
- Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Harguindey, 2005, The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature, Biochim. Biophys. Acta, 1756, 1
- Harris, 2019, GPU-Accelerated Implementation of Continuous Constant pH Molecular Dynamics in Amber: pKa Predictions with Single-pH Simulations, J. Chem. Inf. Model., 59, 4821, 10.1021/acs.jcim.9b00754 · DOI · Paper page
- Harris, 2020, Predicting reactive cysteines with implicit-solvent-Based continuous constant pH molecular dynamics in amber, J. Chem. Theory Comput., 16, 3689, 10.1021/acs.jctc.0c00258 · DOI
- Hashimshony, 2012, CEL-Seq: single-cell RNA-Seq by multiplexed linear amplification, Cell Rep., 2, 666, 10.1016/j.celrep.2012.08.003 · DOI · Paper page
- Haslehurst, 2012, EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer, BMC Cancer, 12, 91, 10.1186/1471-2407-12-91 · DOI · Paper page
- Hayes, 2005, Glutathione transferases, Annu. Rev. Pharmacol. Toxicol., 45, 51, 10.1146/annurev.pharmtox.45.120403.095857 · DOI · Paper page
- Hazai, 2013, Predicting substrates of the human breast cancer resistance protein using a support vector machine method, BMC Bioinformatics, 14, 130, 10.1186/1471-2105-14-130 · DOI
- Hein, 2013, Chapter 1 - proteomic analysis of cellular systems, 3
- Hermann, 2007, Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer, Cell Stem Cell, 1, 313, 10.1016/j.stem.2007.06.002 · DOI · Paper page
- Hinkson, 2017, A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine, Front. Cell Dev. Biol., 5, 83, 10.3389/fcell.2017.00083 · DOI · Paper page
- Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 · DOI · Paper page
- Hoopmann, 2013, Current algorithmic solutions for peptide-based proteomics data generation and identification, Curr. Opin. Biotechnol., 24, 31, 10.1016/j.copbio.2012.10.013 · DOI
- Hossain, 2019, Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality, J. Biomed. Inform., 100, 10.1016/j.jbi.2019.103313 · DOI
- Housman, 2014, Drug resistance in cancer: an overview, Cancers, 6, 1769, 10.3390/cancers6031769 · DOI · Paper page
- Houssein, 2021, Deep and machine learning techniques for medical imaging-based breast cancer: a comprehensive review, Expert Syst. Appl., 167, 10.1016/j.eswa.2020.114161 · DOI · Paper page
- Hraběta, 2020, Drug sequestration in Lysosomes as one of the mechanisms of chemoresistance of Cancer cells and the possibilities of its inhibition, Int. J. Mol. Sci., 21
- Hsu, 2011, miRTar: an integrated system for identifying miRNA-target interactions in human, BMC Bioinformatics, 12, 300, 10.1186/1471-2105-12-300 · DOI
- Hu, 2014, MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells, Tumour Biol., 35, 8953, 10.1007/s13277-014-2158-8 · DOI
- Huang, 1997, Expression of glutathione S-transferase-pi in operative specimens as marker of chemoresistance in patients with ovarian cancer, Zhonghua Fu Chan Ke Za Zhi, 32, 458
- Huang, 2007, Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm, J. Chem. Inf. Model., 47, 1638, 10.1021/ci700083n · DOI · Paper page
- Huby, 2005, Gene expression profiling for pharmaceutical safety assessment, Expert Opin. Drug Metab. Toxicol., 1, 247, 10.1517/17425255.1.2.247 · doi:10.1517/17425255.1.2.247
- Hurley, 2008, ESCRT complexes and the biogenesis of multivesicular bodies, Curr. Opin. Cell Biol., 20, 4, 10.1016/j.ceb.2007.12.002 · DOI · Paper page
- Hussein, 2021, The role of endolysosomal trafficking in anticancer drug resistance, Drug Resist. Updat., 57, 10.1016/j.drup.2021.100769 · DOI
- Hwang, 2018, Single-cell RNA sequencing technologies and bioinformatics pipelines, Exp. Mol. Med., 50, 1, 10.1038/s12276-018-0071-8 · DOI · Paper page
- Hyduke, 2013, Analysis of omics data with genome-scale models of metabolism, Mol. Biosyst., 9, 167, 10.1039/C2MB25453K · DOI · Paper page
- Iadevaia, 2010, Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis, Cancer Res., 70, 6704, 10.1158/0008-5472.CAN-10-0460 · DOI · Paper page
- Icard, 2018, How the Warburg effect supports aggressiveness and drug resistance of cancer cells?, Drug Resist. Updat., 38, 1, 10.1016/j.drup.2018.03.001 · DOI · Paper page
- Ifergan, 2005, Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance, Cancer Res., 65, 10952, 10.1158/0008-5472.CAN-05-2021 · DOI · Paper page
- Institute of Medicine, Board on Health Sciences Policy, Board on Health Care Services, Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, 2012
- Jallon, 1975, Beef liver L-Glutamate dehydrogenase mechanism: presteady state study of the catalytic reduction of 2.oXoglutarate by NADPH, Biochem. Biophys. Res. Commun., 67, 1527, 10.1016/0006-291X(75)90200-4 · doi:10.1016/0006-291x(75)90200-4
200 of 518 shown
Cited by
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00352 · Cited by 132
Self-citationBasis for Accurate Protein p K a Prediction with Machine Learning
Cai, Z., Liu, T., Lin, Q., He, J., Lei, X., Luo, F., & Huang, Y. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00254 · Cited by 31
Wozniak, S., Janson, G., & Feig, M. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.4c01682 · Cited by 14
Metadata
- Authors
- Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário-Ferreira, N., & Moreira, I. S.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 60
- Pages
- 100811
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W4210487294
- Cited by
- 37
- References
- 83
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 283 d)
- Funders
- European Regional Development Fund
- Fundação para a Ciência e a Tecnologia (CEECIND/02300/2017, DSAIPA/DS/0118/2020, LA/P/0058/2020, PD/BD/135179/2017, POCI-01-0145-FEDER-031356, PTDC/QUI-OUT/32243/2017, SFRH/BD/149709/2019, UIDB/04046/2020, UIDB/04539/2020, UIDP/04046/2020)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.